ECSP066600A - Cci-779 para el tratamiento de linfoma celular del manto - Google Patents

Cci-779 para el tratamiento de linfoma celular del manto

Info

Publication number
ECSP066600A
ECSP066600A EC2006006600A ECSP066600A ECSP066600A EC SP066600 A ECSP066600 A EC SP066600A EC 2006006600 A EC2006006600 A EC 2006006600A EC SP066600 A ECSP066600 A EC SP066600A EC SP066600 A ECSP066600 A EC SP066600A
Authority
EC
Ecuador
Prior art keywords
cci
treatment
cell lymphoma
manphell
rapamycin
Prior art date
Application number
EC2006006600A
Other languages
English (en)
Inventor
Thomas E Witzig
Scott H Kaufmann
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of ECSP066600A publication Critical patent/ECSP066600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)

Abstract

Esta invención se relaciona al uso del 42-éster de rapamicina con el ácido 3-hidróxido-2-(hidroximetil)-2-metil propiónico (CCI-779) en el tratamiento o inhibición del linfoma celular del manto.
EC2006006600A 2003-11-04 2006-06-02 Cci-779 para el tratamiento de linfoma celular del manto ECSP066600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51732903P 2003-11-04 2003-11-04

Publications (1)

Publication Number Publication Date
ECSP066600A true ECSP066600A (es) 2006-10-25

Family

ID=34590151

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006600A ECSP066600A (es) 2003-11-04 2006-06-02 Cci-779 para el tratamiento de linfoma celular del manto

Country Status (30)

Country Link
US (2) US20050113403A1 (es)
EP (1) EP1682131B9 (es)
JP (1) JP4856548B2 (es)
KR (1) KR101387988B1 (es)
CN (1) CN1901906B (es)
AR (1) AR046194A1 (es)
AT (1) ATE373477T1 (es)
AU (1) AU2004289213B2 (es)
BR (1) BRPI0415714A (es)
CA (1) CA2543665C (es)
CO (1) CO5690605A2 (es)
CR (1) CR8383A (es)
DE (1) DE602004009098T2 (es)
DK (1) DK1682131T3 (es)
EC (1) ECSP066600A (es)
ES (1) ES2291954T3 (es)
GT (1) GT200400224A (es)
IL (2) IL175128A0 (es)
MY (1) MY136436A (es)
NO (1) NO20062271L (es)
PA (1) PA8616601A1 (es)
PE (1) PE20051000A1 (es)
PL (1) PL1682131T3 (es)
PT (1) PT1682131E (es)
RU (1) RU2358731C2 (es)
SA (1) SA04250375B1 (es)
TW (1) TW200517116A (es)
UA (1) UA83697C2 (es)
WO (1) WO2005046681A1 (es)
ZA (1) ZA200603533B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
WO2008066783A2 (en) * 2006-11-27 2008-06-05 Ariad Pharmaceuticals, Inc. Therapeutic materials and methods
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ATE411321T1 (de) 2000-09-19 2008-10-15 Wyeth Corp Wasserlösliche rapamycin-ester
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA78706C2 (en) * 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
PL367267A1 (en) 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
AR040693A1 (es) * 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
DE602004004520T2 (de) * 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab

Also Published As

Publication number Publication date
KR101387988B1 (ko) 2014-04-22
BRPI0415714A (pt) 2006-12-19
JP2007510721A (ja) 2007-04-26
DE602004009098T2 (de) 2008-06-26
CA2543665A1 (en) 2005-05-26
EP1682131A1 (en) 2006-07-26
SA04250375B1 (ar) 2007-08-13
IL175128A0 (en) 2008-04-13
AU2004289213B2 (en) 2010-08-26
IL220080A0 (en) 2012-07-31
DE602004009098D1 (de) 2007-10-31
RU2006119451A (ru) 2007-12-20
PA8616601A1 (es) 2006-06-02
CN1901906A (zh) 2007-01-24
EP1682131B9 (en) 2009-03-25
ATE373477T1 (de) 2007-10-15
HK1088241A1 (en) 2006-11-03
RU2358731C2 (ru) 2009-06-20
ES2291954T3 (es) 2008-03-01
GT200400224A (es) 2005-06-06
JP4856548B2 (ja) 2012-01-18
AR046194A1 (es) 2005-11-30
WO2005046681A1 (en) 2005-05-26
UA83697C2 (ru) 2008-08-11
US20050113403A1 (en) 2005-05-26
CR8383A (es) 2006-10-04
CN1901906B (zh) 2011-11-16
CO5690605A2 (es) 2006-10-31
DK1682131T3 (da) 2008-01-28
CA2543665C (en) 2009-07-14
TW200517116A (en) 2005-06-01
KR20060111559A (ko) 2006-10-27
AU2004289213A1 (en) 2005-05-26
US8507518B2 (en) 2013-08-13
EP1682131B1 (en) 2007-09-19
MY136436A (en) 2008-10-31
PL1682131T3 (pl) 2008-02-29
NO20062271L (no) 2006-07-21
ZA200603533B (en) 2007-07-25
US20110184010A1 (en) 2011-07-28
PE20051000A1 (es) 2006-02-03
PT1682131E (pt) 2007-11-08

Similar Documents

Publication Publication Date Title
AR031341A1 (es) Uso de cci-779 como agente antineoplastico
NI200700111A (es) Uso de un inhibidor de mtor en el tratamiento del leiomioma del útero
ECSP088598A (es) Derivados de piridazinona
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
GT200600035A (es) Aminopiridinas como inhibidores de beta-secretasa
ECSP066835A (es) Combinaciones antineoplasicas de cci-779 y rituximab
ECSP056114A (es) Combinaciones antineoplásicas
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CR8451A (es) Uso de derivados de n-arilhidracina para combatir pestes
CR8559A (es) Pirazolopirimidinas
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
PA8652701A1 (es) Derivados de quinolina e isoquinolina 5-sustitutos, un procedimiento para su preparacion y su uso como inhibidores de la inflamacion
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
AR034071A1 (es) Combinaciones antineoplasicas
ECSP066600A (es) Cci-779 para el tratamiento de linfoma celular del manto
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
AR051664A1 (es) Agente contra la demodicosis
ECSP066275A (es) Piridinilanilidas
PE20020511A1 (es) Uso de antiprogestinas para la induccion de apoptosis en una celula
ITMI20031576A1 (it) Apparecchiatura di taglio o profilati ad elevata precisione di impiego.
CO5721007A2 (es) 5-6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen
EA200601128A1 (ru) Пиразолопиримидины
ECSP034752A (es) Benzimidazoles utiles en el tratamiento de la dinfuncion sexual
UY29671A1 (es) Compuesto de 7-amino-6-heteroaril-1,2,4-triazolo(1,5-a)pirimidina y su uso para el combate de hongos daninos.-